Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines

Carfilzomib

(2013) K. M. Kortuem et al.   BLOOD

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins

(2013) James A. Nathan et al.   CELL

Immunoproteasomes Are Important for Proteostasis in Immune Responses

(2013) Frédéric Ebstein et al.   CELL

Proteasome inhibitors in acute leukemia

(2013) Denise Niewerth et al.   Expert Review of Anticancer Therapy

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors

(2013) D. Niewerth et al.   HAEMATOLOGICA

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity

(2012) Eva M. Huber et al.   CELL

Emerging roles of immunoproteasomes beyond MHC class I antigen processing

(2012) Frédéric Ebstein et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Immunoproteasomes at the interface of innate and adaptive immune responses: two faces of one enzyme

(2012) Elke Krüger et al.   CURRENT OPINION IN IMMUNOLOGY

Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance

(2012) Andrew J. Kale et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery and Development of Second-Generation Proteasome Inhibitors

(2012) Christopher J. Kirk   SEMINARS IN HEMATOLOGY

The Immunoproteasome as a Target in Hematologic Malignancies

(2012) Deborah J. Kuhn et al.   SEMINARS IN HEMATOLOGY

Bacterial Self-Resistance to the Natural Proteasome Inhibitor Salinosporamide A

(2011) Andrew J. Kale et al.   ACS Chemical Biology

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

(2011) N E Franke et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland

(2011) I. Hrusovsky et al.   ONCOLOGY

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells

(2011) Erika Suzuki et al.   PLoS One

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma

(2011) Jacob P Laubach et al.   Expert Review of Hematology

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit

(2010) Christopher Blackburn et al.   BIOCHEMICAL JOURNAL

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia

(2010) A. M. Roccaro et al.   BLOOD

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo

(2010) Ajita V. Singh et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress

(2010) Ulrike Seifert et al.   CELL

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

(2009) F. Parlati et al.   BLOOD

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

(2009) Tony Muchamuel et al.   NATURE MEDICINE

Molecular mechanisms of proteasome assembly

(2009) Shigeo Murata et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits

(2008) Antonia Busse et al.   CANCER